Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA
Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support.
“Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.”
By hosting in Microsoft’s Netherlands Azure data centre, Impartner customers benefit from the assurance of GDPR-compliant data handling, best-in-class security and the speed advantages of a local infrastructure. The expansion is particularly critical for industries such as finance, manufacturing and telecommunications, where regulatory compliance and system performance are essential.
The investment in European infrastructure is part of Impartner’s broader strategy to expand reach across EMEA, enhance local support and deepen its collaboration with Microsoft to deliver a world-class PRM platform that drives growth for customers globally.
In addition to infrastructure investments, Impartner has strengthened its Europe-based go-to-market and customer teams, including Customer Success, Support and Pre-Sales Engineering. Operating across key European time zones and providing multilingual coverage, these teams enable faster response times, local expertise and close collaboration with customers from onboarding through ongoing adoption. This regional presence complements Impartner’s global delivery model and underpins enterprise-grade SLAs and engagement.
As Impartner expands its infrastructure and customer presence across EMEA, it will continue to invest in community and ecosystem growth, including sponsoring Partnership Leaders’ Catalyst Europe event on October 23, 2025, in London. Together with its regional teams and partners, Impartner remains committed to enabling the next phase of growth for organizations across Europe.
About Impartner
Impartner is the global leader in partner ecosystem management solutions, helping companies transform how they engage, enable, and grow their partner networks. With purpose-built technologies for partner relationship management (PRM) and partner marketing automation (PMA), Impartner empowers organizations to streamline operations, drive demand, and accelerate revenue by delivering measurable ROI from channel programs. Millions of partners across the globe rely on Impartner daily, making it the most widely adopted PRM platform in the world. From onboarding and guided journeys to performance insights and business planning, Impartner delivers automation and best practices that scale. Learn more at impartner.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251021211364/en/
Contacts
For media inquiries, please contact:
Lola Phonpadith
Lola.phonpadith@impartner.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 13:00:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 12:12:00 EEST | Press release
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021806533/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain. PSP is a rare, rapidly progressive and ultimately fatal neurodegenerative disease2. To date, no disease-modifying therapies have been approved for PSP. The PROSPER study is a randomized, double-blind, placebo-controlled trial3 that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on October 6th, two months ahead
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 11:51:00 EEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 11:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
INNIO Secures Largest Order in Company History with VoltaGrid Delivering Power Generation for One of the World’s Largest Data Centers21.10.2025 10:01:00 EEST | Press release
INNIO Group today announced the largest order by power delivery in its history: a groundbreaking 2.3 GW power infrastructure project featuring 92 power packs, each delivering 25 MW of output. The initiative with VoltaGrid strengthens INNIO’s position as a key energy solutions provider for the rapidly expanding U.S. data center sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021503080/en/ INNIO Secures Largest Order in Company History (c) INNIO “This landmark order underscores the strength of INNIO’s technology and our ability to power the AI revolution with smart, high-performance energy solutions,” said Dr. Olaf Berlien, President and CEO of INNIO Group. “We are proud to partner with VoltaGrid in shaping the energy infrastructure of tomorrow.” “This is a major step toward building the energy infrastructure for the AI era,” added Nathan Ough, CEO of VoltaGrid. “Together with INNIO, we’re delivering a scalable solut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom